Results 31 to 40 of about 1,857,357 (268)

USP51/PD‐L1/ITGB1‐deployed juxtacrine interaction plays a cell‐intrinsic role in promoting chemoresistant phenotypes in non‐small cell lung cancer

open access: yesCancer Communications, 2023
Background Programmed death ligand 1 (PD‐L1) has been demonstrated to facilitate tumor progression and therapeutic resistance in an immune‐independent manner.
Jianjun Li   +13 more
doaj   +1 more source

Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumors

open access: yesJournal for ImmunoTherapy of Cancer, 2023
Background Cellular immunotherapies for cancer represent a means by which a patient’s immune system can be augmented with high numbers of tumor-specific T cells.
Benjamin Boyerinas   +12 more
doaj   +1 more source

Modeling the Tumor Microenvironment and Cancer Immunotherapy in Next-Generation Humanized Mice

open access: yes, 2023
Cancer immunotherapy has brought significant clinical benefits to numerous patients with malignant disease. However, only a fraction of patients experiences complete and durable responses to currently available immunotherapies.
Dietmar Herndler-Brandstetter   +2 more
core   +1 more source

Glycocalyx Acts as a Central Player in the Development of Tumor Microenvironment by Extracellular Vesicles for Angiogenesis and Metastasis

open access: yes, 2022
Angiogenesis in tumor growth and progression involves a series of complex changes in the tumor microenvironment. Extracellular vesicles (EVs) are important components of the tumor microenvironment, which can be classified as exosomes, apoptotic vesicles,
Zeng, Ye   +7 more
core   +1 more source

Jagged1-Notch1-deployed tumor perivascular niche promotes breast cancer stem cell phenotype through Zeb1

open access: yesNature Communications, 2020
The transcription factor Zeb1 is known to promote tumorigenesis and stemness in breast cancer. Here the authors show that tumor endothelial Jagged1 induces activation of Notch1 signaling and increases Zeb1 expression in neighboring breast cancer stem ...
Huimin Jiang   +14 more
doaj   +1 more source

Heterogeneity of Cancer-Associated Fibroblasts and the Tumor Immune Microenvironment in Pancreatic Cancer

open access: yes, 2022
SIMPLE SUMMARY: Stroma-targeting therapy in pancreatic ductal adenocarcinoma (PDAC) has been extensively investigated, but no candidates have shown efficacy at the clinical trial stage.
Masafumi Nakamura   +5 more
core   +1 more source

Fully murine CD105-targeted CAR-T cells provide an immunocompetent model for CAR-T cell biology

open access: yesOncoImmunology, 2022
The modeling of chimeric antigen receptor (CAR) T cell therapies has been mostly focused on immunodeficient models. However, there are many advantages in studying CAR-T cell biology in an immunocompetent setting. We generated a fully murine CAR targeting
Konstantinos Lontos   +10 more
doaj   +1 more source

Immune Cells in the Tumor Microenvironment of Soft Tissue Sarcomas

open access: yes, 2023
Soft tissue sarcomas (STSs) are a rare heterogeneous group of malignant neoplasms characterized by their aggressive course and poor response to treatment. This determines the relevance of research aimed at studying the pathogenesis of STSs. By now, it is
Timur Fatkhudinov   +4 more
core   +1 more source

Cancer-Associated Adipocytes and Breast Cancer: Intertwining in the Tumor Microenvironment and Challenges for Cancer Therapy

open access: yes, 2023
Adipocytes are the main components in breast tissue, and cancer-associated adipocytes (CAAs) are one of the most important components in the tumor microenvironment of breast cancer (BC). Bidirectional regulation was found between CAAs and BC cells.
Xiaosong Chen   +7 more
core   +1 more source

GM‐CSF enhances tumor invasion by elevated MMP‐2, ‐9, and ‐26 expression

open access: yesCancer Medicine, 2013
Granulocyte–macrophage colony‐stimulating factor (GM‐CSF) promotes tumor progression in different tumor models in an autocrine and paracrine manner. However, at the same time GM‐CSF is used in cancer therapies to ameliorate neutropenia.
Claudia M. Gutschalk   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy